Sequential tPA-mproUK Thrombolysis for Faster Clot Lysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current thrombolytic drugs for treating blood clots, such as tPA and its derivatives, cause significant bleeding complications due to non-specific activation of plasminogen and degradation of hemostatic fibrin, limiting their use and efficacy, especially in treating conditions like stroke and acute myocardial infarction.
Innovation Solution
A combination therapy using a mini-dose of tissue plasminogen activator (tPA) and a low dose of pro-urokinase mutant (mproUK) with histidine substitution at position 300 (Lys300→His), administered together, to achieve faster and safer thrombolysis with minimal hemorrhagic side effects, optionally supplemented with C1-inhibitor to manage any non-specific activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high-dose tPA monotherapy is used to achieve maximum clot lysis rate, then thrombolysis efficacy is improved, but bleeding complications increase significantly
Solution Approach 1:
The patent combines tPA and mproUK into a sequential therapy regimen where tPA is administered first to initiate clot lysis, followed by mproUK to complete the lysis process. This merging of two different thrombolytic agents with distinct mechanisms allows achievement of maximum clot lysis rate while using lower individual doses of each agent, thereby reducing bleeding complications compared to high-dose monotherapy
Solution Approach 2:
The patent changes the dosing parameters from high-dose monotherapy to low-dose sequential therapy. Specifically, tPA is given at reduced doses (e.g., 0.5-2.0 mg) followed by mproUK at low doses (e.g., 2-10 mg), which together achieve the same or better clot lysis efficacy while maintaining fibrinogen levels above critical thresholds, thus preventing hemorrhagic complications
2Productivity
If tPA is used for thrombolysis, then blood clot dissolution is achieved, but hemostatic fibrin degradation occurs causing hemophilia-like side effects
Solution Approach 1:
The patent uses mproUK as an intermediary agent that preferentially activates plasminogen bound to fibrin clots while sparing free fibrinogen in plasma. This selective action allows complete dissolution of thrombotic clots without significant degradation of hemostatic fibrin, thereby preventing hemophilia-like side effects that occur with tPA monotherapy
3Reliability
If diagnostic testing is performed to determine stroke cause before treatment, then treatment safety is improved, but treatment time is delayed
Solution Approach 1:
The patent implements preliminary action by pre-hospital administration of the thrombolytic regimen based on clinical suspicion of ischemic stroke without waiting for definitive imaging diagnosis. The sequential tPA-mproUK protocol is initiated immediately in the field or emergency department, and treatment can be continued or adjusted once imaging results confirm ischemic rather than hemorrhagic stroke, thereby eliminating treatment delays while maintaining safety through the inherent safety profile of the low-dose sequential regimen
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination achieves a maximum clot lysis rate with minimal fibrinogen degradation of less than 30%, ensuring safe and effective treatment of conditions like stroke and acute myocardial infarction without the risks associated with high-dose monotherapy.
Implementation Method 1
thrombolytic drugs such as tPA and its derivatives in current use function by activating the proenzyme plasminogen to the protease plasmin
Implementation Method 2
A second composition includes a low dose of a pro-urokinase mutant... The mproUK can comprise a substitution of histidine for lysine at amino acid position 300
Data Source
AI summary
Provided herein are methods for safe and effective thrombolysis in therapy for human subjects with symptoms of a potential stroke or acute myocardial infarction (“AMI”) using a sequential administration of a low dose bolus of human tissue plasminogen activator (“tPA”) followed by an infusion of a mutant form of human pro-urokinase (“proUK”).